Heat Biologics, Inc. (NASDAQ:HTBX) registered a -7.41% decrease, still its new closing price is 150.00% up from the company’s 1 year high of 3.35.It posted 7.53% gains in previous 5 sessions and is now the subject of 0 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 0 buy or better ratings. The 1 stock analysts following this company have an average price target at $4.00, with individual PT in the $4.00-$4.00 range. The shares moved at $1.00, implying that brokerage firms see shares losing about -59.18% in twelve months time.
Heat Biologics, Inc. (HTBX) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a 16.28% rise year to date. A Director at Heat Biologics, Inc. (HTBX) acquired shares in a transaction closed on Wednesday March 23, 2016. KHARITONOV MICHAEL bought 900,000 shares in the company at $0.75 each and collected $675,000 in proceeds. KHARITONOV MICHAEL now owns 949,960 shares in the company after this transaction. A VP Clinical/Regulatory Affairs in the company, Price Melissa, disclosed a transaction on Thursday June 05, 2014 that ended up paying $2,001 from the purchase of 692 shares at $4.3 per share.
Heat Biologics, Inc. (NASDAQ:HTBX) Upcoming Results on Tap
Heat Biologics, Inc. will next provide financial results for the December 2017 quarter. Stock analysts expect it to report per-share earnings of $-2.88 in that period. Sales during the quarter are predicted to arrive at $0.
Heat Biologics, Inc. (HTBX) Brokerage Update
Over the last six months and over the last three months, the shares of Heat Biologics, Inc. (HTBX), have changed 40.85% and -27.01%, respectively.
